北美淋巴水肿治疗市场，按治疗类型（压迫疗法、外科手术、药物疗法、激光疗法等）、类型（原发性淋巴水肿和继发性淋巴水肿）、患处（生殖器、下肢、上肢）、年龄组（成人、儿童和老年人）、给药途径（口服、注射和外用）、最终用户（医院、门诊手术中心、专科诊所等）、分销渠道（直接招标、药店等）划分，行业趋势及预测至 2029 年
北美淋巴水肿治疗市场分析和见解
淋巴水肿通常影响一只手臂或一条腿。在某些情况下，手臂和腿都可能受到影响。一些患者可能会出现头部、生殖器或胸部肿胀。
淋巴水肿无法治愈，但可以通过正确的治疗来控制，有助于减轻肿胀和疼痛。
综合减充血疗法 (CDT)：从强化治疗阶段开始，患者每天接受治疗和培训。接下来是维持阶段，鼓励患者使用他们学到的技术来接受护理。
一些参与淋巴系统发育的基因发生突变，可能会导致原发性淋巴水肿。这些有缺陷的基因会干扰淋巴系统的发育，破坏其正常排出液体的能力。
继发性淋巴水肿有多种可能的原因，包括癌症手术、放射治疗、感染、炎症、心血管疾病、损伤和创伤
癌症发病率的上升和医疗费用的增加加速了医疗机构对淋巴水肿治疗的需求。创新和技术的激增也推动了市场的增长。
由于市场参与者不断增加以及先进成像产品的供应，北美淋巴水肿治疗市场在预测年将不断增长。与此同时，制造商正致力于研发活动，以向市场推出新产品。
全球癌症相关淋巴水肿患者数量的增加以及研发活动的增加正在推动预测期内北美淋巴水肿治疗市场的需求。然而，无法治愈和治疗费用高昂可能会阻碍预测期内北美淋巴水肿治疗市场的增长。
Data Bridge Market Research 分析称，2022 年至 2029 年的预测期内，北美淋巴水肿治疗市场将以 9.7% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按治疗类型（压迫疗法、手术、药物疗法、激光疗法等）、类型（原发性淋巴水肿和继发性淋巴水肿）、患处（生殖器、下肢、上肢）、年龄组（成人、儿童和老年人）、给药途径（口服、注射和外用）、最终用户（医院、门诊手术中心、专科诊所等）、分销渠道（直接招标、药店等） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
Tactile Medical、BIOCOMPRESSION SYSTEMS、Lohmann & Rauscher GmbH & Co. KG、ThermoTek、Essity (BSN medical GmbH)、Cardinal Health、Smith+Nephew、Avet Pharmaceuticals Inc.、KOYA MEDICAL、SIGVARIS GROUP、AIROS Medical, Inc.、Tactile Medical、medi GmbH & Co. KG、PAUL HARTMANN AG、Convatec Inc.、3M、JUZO、Mego Afek ltd、Huntleigh Healthcare Limited、HERANTIS PHARMA Plc 等 |
市场定义
淋巴水肿是指由通常通过身体淋巴系统排出的富含蛋白质的液体积聚引起的组织肿胀。它最常影响手臂或腿部，但也可能发生在胸壁、腹部、颈部和生殖器。
淋巴结是淋巴系统的重要组成部分。癌症治疗切除或损坏淋巴结可能会导致淋巴水肿。任何阻碍淋巴液排出的问题都可能导致淋巴水肿。
治疗可能包括压缩绷带、按摩、压力袜、连续气动泵、精心的皮肤护理以及手术去除肿胀组织或创建新的引流路径。
癌症的高发性、创新和技术的不断增加、市场参与者数量的不断增加以及新产品的推出也推动了市场的增长。
北美淋巴水肿治疗市场动态
驱动程序
- 淋巴水肿病例数量增加
淋巴液聚集在皮肤下方脂肪组织中称为淋巴水肿。这种疾病是由人体淋巴系统流动不畅引起的，表现为腿部、手臂或两者兼有。在美国，原发性淋巴水肿影响 100 万至 200 万人，而继发性淋巴水肿影响 200 万至 300 万人。
- 癌症发病率上升
根据美国国家癌症研究所的数据，2020 年美国将发现 1,806,590 例新癌症病例，其中 606,520 人死于癌症。
根据美国癌症协会的数据，癌症是加拿大的主要死亡原因，也是美国仅次于心脏病的第二大死亡原因。2018 年，预计北美将出现 190 万例新发癌症病例和 693,000 例癌症死亡病例。
此外，医疗机构数量的增加和多种疗法的出现也是扩大淋巴水肿治疗市场的重要因素。此外，医疗保健系统需要非常先进的治疗产品。因此，主要参与者高度关注新产品和创新产品的发布和批准，以推动北美淋巴水肿治疗市场的发展。
机会
- 药品批准
过去几年，由于疾病死亡率的上升，市场见证了大量药物的批准。药物批准的增加将增加对淋巴水肿治疗市场的需求。
2015年7月，Siltuximab成为美国FDA优先审查计划下首个获批用于治疗多中心Castleman病的药物。多中心Castleman病是指淋巴结肿大，在多个淋巴结区域有特征性表现的疾病。
此外，北美主要参与者的合作伙伴关系和协议将为市场增长率带来新的机遇。
限制/挑战
然而，治疗费用高昂以及对淋巴水肿缺乏认识限制了市场的发展。此外，淋巴水肿无法永久治愈以及报销困难是北美淋巴水肿治疗市场面临的挑战
北美淋巴水肿治疗市场报告提供了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地理扩展、市场技术创新等方面的机会。要获取有关市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报；我们的团队将帮助您做出明智的市场决策，以实现市场增长。
COVID-19 对北美淋巴水肿治疗市场的影响
COVID-19 对市场产生了积极影响。2020 年 3 月 11 日，COVID-19 正式被宣布为大流行。自那时起，COVID-19 大流行导致对医疗资源的需求空前高涨。
在 COVID 19 期间，原发性和继发性淋巴水肿患者的治疗均被中断或延迟。就诊患者数量大幅减少，影响了北美淋巴水肿治疗市场的整体增长。COVID-19 的影响对淋巴水肿治疗产品的价格产生了负面影响，因为封锁期间治疗淋巴水肿的药物和处方药成本增加，就诊人数减少。
据联合国毒品和犯罪问题办公室 (UNODC) 称，新冠疫情期间的流动性限制、边境封闭以及全球贸易整体下滑扰乱了毒品市场的供应链。
此外，许多药物的生产地点不同，由于人员流动受限，药物供应出现短缺。因此，COVID-19 对北美淋巴水肿治疗市场的供应链产生了负面影响。
最新动态
- 2020 年 2 月，Avet Pharmaceuticals Inc. 宣布收购了 23 个简化新药申请 (ANDA) 组合，涵盖 17 个产品系列，均已获得美国食品药品管理局 (FDA) 的批准。这扩大了公司的产品组合
- 2021 年 9 月，Tactile Medical 宣布招募首位患者参加一项随机对照临床试验，以评估 Flexitouch plus 治疗头颈部淋巴水肿的有效性。这将提高该公司在市场上的可信度
北美淋巴水肿治疗市场 范围
北美淋巴水肿治疗市场根据治疗类型、类型、受影响区域、年龄组、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
治疗类型
- 加压疗法
- 外科手术
- 药物治疗
- 激光治疗
- 其他的
根据治疗类型，北美淋巴水肿治疗市场分为压迫疗法、手术、药物治疗、激光治疗等。
类型
- 继发性淋巴水肿
- 原发性淋巴水肿
根据类型，北美淋巴水肿治疗市场分为继发性淋巴水肿和原发性淋巴水肿。
受影响区域
- 下肢
- 上肢
- 生殖器
根据受影响区域，北美淋巴水肿治疗市场细分为下肢、上肢和生殖器
年龄组
- 成人
- 老年
- 儿科
根据年龄组，北美淋巴水肿治疗市场分为成人、老年人和儿童。
给药途径
- 口服
- 注射剂
- 主题
根据给药途径，北美淋巴水肿治疗市场分为口服、注射和外用。
最终用户
- 医院
- 专科诊所
- 门诊手术中心
- 其他的
根据最终用户，北美淋巴水肿治疗市场分为医院、专科诊所、门诊手术中心和其他。
分销渠道
- 药店
- 直接招标
- 其他的
根据分销渠道，北美淋巴水肿治疗市场分为药店、直接招标和其他。
北美淋巴水肿治疗市场 区域分析/见解
对北美淋巴水肿治疗市场进行了分析，并按国家、治疗类型、类型、受影响区域、年龄组、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。
北美淋巴水肿治疗市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于市场参与者的强大影响力和淋巴水肿疾病患病率的上升，美国预计将主导北美淋巴水肿治疗市场。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
竞争格局和北美淋巴水肿治疗市场 份额分析
北美淋巴水肿治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上数据点仅与公司对北美淋巴水肿治疗市场的关注有关。
北美淋巴水肿治疗市场的一些主要参与者包括 Tactile Medical、BIOCOMPRESSION SYSTEMS、Lohmann & Rauscher GmbH & Co. KG、ThermoTek、Essity (BSN medical GmbH)、Cardinal Health、Smith+Nephew、Avet Pharmaceuticals Inc.、KOYA MEDICAL、SIGVARIS GROUP、AIROS Medical, Inc.、Tactile Medical、medi GmbH & Co. KG、PAUL HARTMANN AG、Convatec Inc.、3M、JUZO、Mego Afek ltd、Huntleigh Healthcare Limited、HERANTIS PHARMA Plc 等。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师电话或提出您的询问。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、非洲与地区以及供应商份额分析。要了解有关研究方法的更多信息，请提出询问以与我们的行业专家交谈。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S ANALYSIS
4.2 PORTER'S MODEL
5 PIPELINE ANALYSIS FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
7.1 U.S.
7.2 CANADA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
8.1.4 MULTIPLE THERAPIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF TREATMENT
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE
8.3 OPPORTUNITIES
8.3.1 DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA
8.4.2 DIFFICULT REIMBURSEMENT
9 IMPACT OF COVID-19 ON THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 COMPRESSION THERAPY
10.2.1 BY PRODUCT
10.2.1.1 COMPRESSION PUMPS
10.2.1.2 COMPRESSION GARMENTS
10.2.1.2.1 COMPRESSION STOCKINGS
10.2.1.2.2 COMPRESSION SLEEVES
10.2.1.2.3 OTHERS
10.2.1.3 COMPRESSION BANDAGES & WRAPS
10.2.1.4 OTHERS
10.2.2 BY TECHNIQUE
10.2.2.1 STATIC COMPRESSION THERAPY
10.2.2.2 DYNAMIC COMPRESSION THERAPY
10.3 SURGERY
10.3.1 LYMPHOVENOUS TRANSPLANT
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS
10.3.3 LIPOSUCTION
10.3.4 OTHERS
10.4 DRUG THERAPY
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
10.4.2 RETINOIDS
10.4.3 ANTIBIOTICS
10.4.4 OTHERS
10.5 LASER THERAPY
10.6 OTHERS
11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 SECONDARY LYMPHEDEMA
11.3 PRIMARY LYMPHEDEMA
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)
11.3.2 CONGENITAL LYMPHEDEMA
11.3.3 LYMPHEDEMA TARDA
12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
12.1 OVERVIEW
12.2 LOWER EXTREMITY
12.3 UPPER EXTREMITY
12.4 GENITALIA
13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
13.4 PEDIATRIC
14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INJECTABLE
14.4 TOPICAL
15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTERS
15.5 OTHERS
16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 PHARMACY STORES
16.3 DIRECT TENDER
16.4 OTHERS
17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION
17.1 OVERVIEW
17.2 U.S.
17.3 CANADA
17.4 MEXICO
18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYIS
20 COMPANY PROFILE
20.1 TACTILE MEDICAL
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.1.5 CLINICAL TRIAL:
20.2 ESSITY (BSN MEDICAL GMBH)
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 3M
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.3.5 NEW BUSINESS SEGMENT
20.3.6 ACQUISITION
20.4 CARDINAL HEALTH
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 LOHMANN & RAUSCHER GMBH & CO. KG
20.5.1 COMPANY SNAPSHOT
20.5.2 PRODUCT PORTFOLIO
20.5.3 RECENT DEVELOPMENT
20.6 AIROS MEDICAL, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.4 PRODUCT LAUNCH:
20.7 AVET PHARMACEUTICALS INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 BIOCOMPRESSION SYSTEMS
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.8.4 AGREEMENT
20.9 CONVATEC INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 HERANTIS PHARMA PLC
20.10.1 COMPANY SNAPSHOT
20.10.2 RECENT DEVELOPMENT
20.11 HUNTLEIGH HEALTHCARE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 JUZO
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 KOYA MEDICAL
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.4 APPROVAL
20.14 MEDI GMBH & CO. KG
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 MEGO AFEK LTD
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.15.4 APPLICATION LAUNCH:
20.16 PAUL HARTMANN AG
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 SIGVARIS GROUP
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.17.4 PRODUCT LAUNCHES:
20.18 SMITH +NEPHEW
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENT
20.19 THERMOTEK
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:
TABLE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 16 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 17 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 18 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 19 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 20 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 21 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 22 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 25 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 26 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 30 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 31 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 32 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 35 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 38 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 39 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 40 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 43 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 44 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 45 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 46 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 47 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 48 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 51 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 52 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 53 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: REGIONAL VS COUNTRY ANALYSIS
FIGURE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
FIGURE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021
FIGURE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021
FIGURE 19 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021
FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 26 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021
FIGURE 27 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 31 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021
FIGURE 35 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)
FIGURE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 43 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 44 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)
FIGURE 47 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
